Suchen
InMed Pharmaceuticals Inc
INMZur Watchlist hinzufügen
1.560USD
-0.030-1.89%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
4.37MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über InMed Pharmaceuticals Inc Unternehmen
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc Informationen
BörsenkürzelINM
Name des UnternehmensInMed Pharmaceuticals Inc
IPO-datumJun 21, 2001
CEOAdams (Eric A)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJun 21
Addresse1445-885 West Georgia St.
StadtVANCOUVER
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV6C 3E8
Telefon16046697207
Websitehttps://www.inmedpharma.com/
BörsenkürzelINM
IPO-datumJun 21, 2001
CEOAdams (Eric A)
Führungskräfte von InMed Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von InMed Pharmaceuticals Inc?
Die fünf größten Anteilseigner von InMed Pharmaceuticals Inc sind: Mr. Andrew Harold Hull
Wie viele Institutionen halten Anteile an InMed Pharmaceuticals Inc (INM)?
Mit Stand vom 2026Q1 halten 31 Institutionen Anteile an InMed Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 320.11K, was 9.66% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -43643.00 gestiegen.